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Scedosporium species show decreased susceptibility to the majority of systemic antifungal drugs. Acquired resistance is likely to
disseminate differentially with the mode of exchange of genetic material between lineages. Inter- and intraspecific diversities of
Scedosporium species were analyzed for three partitions (rDNA internal transcribed spacer gene [ITS], partial-tubulin gene,
and amplified fragment length polymorphism profiles), with the aim to establish distribution of resistance between species, pop-
ulations, and strains. Heterogeneity of and recombination between lineages were determined, and distances between clusters
were calculated using a centroid approach. Clinical, geographic, and antifungal data were plotted on diversity networks. Sce-
dosporium minutisporum, Scedosporium desertorum, and Scedosporium aurantiacum were distinguished unambiguously in all
partitions and had differential antifungal susceptibility profiles (ASP). Pseudallescheria fusoidea and Pseudallescheria ellip-
soidea were indistinguishable from Scedosporium boydii. Pseudallescheria angusta took an intermediate position between Sce-
dosporium apiospermum and S. boydii. Scedosporium boydii and S. apiospermum had identical ASP. Differences in (multi)resis-
tance were linked to individual strains. S. apiospermum and S. boydii showed limited interbreeding and were recognized as
valid, sympatric species. The S. apiospermum/S. boydii group, comprising the main clinically relevant Scedosporium species,
consists of separate lineages and is interpreted as a complex undergoing sympatric evolution with incomplete lineage sorting. In
routine diagnostics, the lineages in S. apiospermum/S. boydii are indicated with the umbrella descriptor “S. apiospermum com-
plex”; individual species can be identified with rDNA ITSwith 96.3% confidence. Voriconazole is recommended as the first-line
treatment; resistance against this compound is rare.
Members of the fungal genus Scedosporium are increasinglyrecognized as opportunistic agents of disease, e.g., in trans-
plant recipients (1).Detection has been enhanced by the introduc-
tion of semiselective isolation media (2) and molecular detection
methods (3). The latter have led to the recognition of Scedospo-
rium as the second most prevalent mold genus (after Aspergillus)
colonizing the lungs of patients with cystic fibrosis (4). Scedospo-
rium colonization is a contraindication of lung transplantation,
which is the ultimate treatment option for these patients (5, 6).
Scedosporium species are unique as causative agents of the near-
drowning syndrome (7, 8), a cerebral infectionwhich is life threat-
ening due to a lack of therapeutic options. The impacts of invasive
scedosporiosis on costs of patient care and mortality in Australia
were found to be significant (9). Scedosporium species and rela-
tives, particularly Lomentospora prolificans (Scedosporium prolifi-
cans), are among the fungi with the highest degrees of resistance to
a wide collection of antifungal compounds (10).
During the last decade, several molecular species have been
recognized in Scedosporium. Several of these have gained wide
recognition, particularly Scedosporium apiospermum, S. aurantia-
cum, S. boydii, S. dehoogii, S. minutisporum, and L. prolificans (11–
14). The most common species, Scedosporium apiospermum and
Scedosporium boydii, aremolecular siblings which aremorpholog-
ically identical (13). Degrees of intraspecific heterogeneity are
variable between species. Gilgado et al. (13) already noted that S.
boydii comprises lineages within larger mutual distances than S.
apiospermum. In contrast, L. prolificans, compared with the same
parameters, is nearly monomorphic (15). Scedosporium boydii is
believed to be homothallic (13) and produces elaborate ascigerous
fruit bodies under appropriate culture conditions, classically
known under the generic name Pseudallescheria. Some decades
ago, with only a few isolates available for study,minute differences
in ascoma morphology were judged sufficient for the description
of species such as Pseudallescheria angusta, P. ellipsoidea, and P.
fusoidea (16). Today, morphological differences of these devia-
tions appear close to the range of variability of prevalent Scedospo-
rium species.
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The aim of the present study was to evaluate degrees of genetic
separation of species and lineages in Scedosporium and to compare
these with distribution patterns of antifungal resistance, which
may be understood better in the light of sexuality and gene flow.
Genetic separation is established by analysis of the number of
recombination events between molecular clusters, using se-
quences of the rDNA internal transcribed spacer gene (ITS) and
the partial -tubulin gene (BT2) and profiles generated by ampli-
fied fragment length polymorphism (AFLP) genotyping.
MATERIALS AND METHODS
Strains. The studied Scedosporium test set for sequence analyses com-
prised a total of 123 strains (see Table S1 in the supplementalmaterial). Of
this set, 72 were of clinical and 51 of environmental origin. In total, 27
countries were represented by strains (see Table S1). The following type
strains were included: P. angusta (CBS 254.72), S. apiospermum (CBS
117407), Pseudallescheria boydii (CBS 101.22), Scedosporium dehoogii
(CBS 117406), Pseudallescheria ellipsoidea (CBS 418.73), Pseudallescheria
fusoidea (CBS 106.53), Scedosporium minutisporum (CBS 116911), and
Scedosporium desertorum (CBS 489.72). The set of type strains was sup-
plemented by several authentic strains of Scedosporium deficiens (CBS
101723), 8 strains listed by Rainer and Kaltseis (14), and a set of reference
strains that were verified by sequencing the rDNA internal transcribed
spacer gene region and the partial -tubulin gene region. All strains were
identified down to species level using AFLP genotyping.
In vitro susceptibility data. In vitro susceptibility data were taken
from a previous study (10). In brief, data were generated according to
CLSI guidelines (17) for all echinocandins, azoles, and polyenes. For anal-
yses in the current study, voriconazole, posaconazole, anidulafungin, and
micafungin were chosen due to their promising in vitro activity against
Scedosporium strains. Caspofungin was excluded as it is currently not
recommended as a compound for MIC determination (18, 19).
DNA extraction. Strains were grown on Sabouraud’s agar tubes at
30°C until sporulation was visible. Conidia were harvested and mechani-
cally lysed using a MagNA lyser instrument (Roche Diagnostics) as pre-
viously described (10). DNA extraction and purification were performed
with a MagNA Pure DNA isolation kit III (used as described in the man-
ufacturer’s manual) in aMagNA Pure LC instrument. All experiments on
living material were performed according to international biosafety poli-
cies (biosafety level 2).
Sequencing. For PCR amplification and sequencing, standard proce-
dures were used. Briefly, for ITS amplification, primers V9 (5=-TGCGTT
GATTACGTCCCTGC-3=) and RLR3R (5=-GGTCCGTGTTTCAAGAC-
3=) were applied, and for the partial -tubulin gene (BT2, covering exons
3 to 69), primers Bt2a and Bt2b were used (20). As sequencing primers,
ITS1 and ITS4 (21) were used for ITS, and for BT2 the same primers were
used as for amplification. Sequencing was done with an ABI 3700 XL
instrument in combination with a BigDye v. 3.1 Terminator sequencing
kit (Applied Biosystems, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Electropherograms were edited using SeqMan v. 8.1
(DNAStar, Madison, WI, USA). To minimize the risk of PCR amplicon
cross-contamination, pre- and post-PCR procedures were performed in
physically separated facilities.
DNA sequence analysis. Sequences were exported and aligned auto-
matically in theMuscle package (www.ebi.ac.uk/tools/msa/muscle/). Ini-
tial identification of the strains was performed by use of a BLAST search
using in-house research databases (Biolomics and BioNumerics) at the
CBS-KNAW Fungal Biodiversity Centre (Utrecht, The Netherlands). Se-
quences were deposited in NCBI GenBank (see Table S1 in the supple-
mental material).
Amplified fragment length polymorphism.Genotyping byAFLPwas
performed as described before by Lu et al. (22). However, for the selective
amplification reaction, another set of primers was used, namely, 1 M
HpyCH4IV primer with one selective residue (underlined) (5=-Flu-GTA
GACTGCGTACCCGTT3=) and 1 M MseI primer with four selective
residues (underlined) (5=-GATGAGTCCTGACTAATGAA-3=). Subse-
quent fragment analysis was carried out as described by Lu et al. (22).
Data analysis. AFLP data were imported in Bionumerics v. 6.6 (Ap-
pliedMaths, Sint-Martens-Latem, Belgium), and DNA fragments (range,
60–300 bp) were analyzed by unweighted-pair groupmethod using aver-
age linkages (UPGMA) clustering using the Pearson correlation coeffi-
cient. AFLP fingerprints of poor quality were excluded from analysis.
Homology to type/reference strains was used for identification. AFLP
groups are listed in Table S1 in the supplemental material. Genetic relat-
ednesswas visualized by constructing aminimumspanning tree in Bionu-
merics v. 6.6. As input data for theminimum spanning tree, the similarity
matrix of the UPGMA-based tree was used and treated as categorical
information. Data on antifungal resistance were taken from Lackner et al.
(10).
Sequence data were analyzed in MEGA v. 5.2 (http://www
.megasoftware.net) and phylogenetic trees were constructed with maxi-
mum likelihood using the Tamura-Nei model TN93 and 1,000 bootstrap
replicates. The built-in model test in MEGA v. 5.2 was used with the
following parameters. A neighbor-joining treewas created by the program
(statistical method based on maximum likelihood), gaps/missing data
were treated as complete deletions, and the branch swap filter was set to
moderate. The rate variation model allowed for some sites to be evolu-
tionarily invariable (I) (56.85% of sites). The tree with the highest log
likelihood (ln L, 868.686) is shown. Groups in Table S1 in the supple-
mental material were based on this tree. ITS-based subdivisions were
made on the basis of the same strains clustered by Ward’s averaging in
Bionumerics v. 6.6. DNASP v. 5.10 (http://www.ub.edu/dnasp) was used
to calculate population-related statistics. The AFLP groups were consid-
ered separate populations. The neighbor-joining network treewas created
with SplitsTree v. 4.8 (http://www.splitstree.org). The pairwise ho-
moplasy index (PHI) test was also performed with SplitsTree v. 4.8. Hap-
lotype networks were created with Network v. 4.6.10 by using a median-
joining algorithm, with all single nucleotide polymorphisms (SNPs)
having the same weight (http://www.fluxus-engineering.com/sharenet
.htm).
A centroid approach was applied separately to sequences of BT2 and
ITS subjected to pairwise comparison, and similarity values were calcu-
lated. Themethod was described by T. D. Vu and V. Robert (unpublished
data) and was implemented in Biolomics (23). For each of the two loci, a
similarity value was predicted which optimally supported the classifica-
tion of sequences based on associated provisional taxon names (i.e., AFLP
groups). The centroid sequence of each group is the one that is connected
with all others of the same group at the highest average similarity value.
Hypothetical clustering was compared in several combinations, focusing
on the complex of S. apiospermum and S. boydii (AFLP1, 3, 6, and 9).
Comparisons were made by either combining AFLP3 with 1/6 (S. boydii)
or with 9 (S. apiospermum) or considering AFLP3 as a separate group.
MICs of antifungals as log2 values were analyzed according to CLSI
guidelines using broth microdilution. For statistical analysis, results were
categorized as low MICs (L), medium MICs (M), and high MICs (H)
based on MICs published by Lackner et al. (10). As no epidemiological
cutoff (ECOFF) values, breakpoints, or clinical breakpoints have been
published for Scedosporium, the categories were defined as follows: vori-
conazole (2 mg/liter, L [lowMICs]; 4 mg/liter, M [mediumMICs];4
mg/liter, H [high MICs]), amphotericin B (AMB) (2 mg/liter, L; 4
mg/liter, H), posaconazole (2 mg/liter, L; 4 mg/liter, M; 4 mg/liter,
H), anidulafungin (1 mg/liter, L; 2 mg/liter, M; 2 mg/liter, H), and
micafungin (1 mg/liter, L; 2 mg/liter, M;2 mg/liter, H). Correlation,
cross-resistance, and multiresistance were plotted in minimum spanning
trees.
Susceptibility data (267 records) were analyzed retrospectively. Data
were summarized in cross tables, andmedianswere calculated forMICs of
amphotericin B, voriconazole, posaconazole, anidulafungin, and mica-
fungin. Box plots of log-transformed values were used for graphical dis-
play. Since MIC data were not normally distributed (as determined with
Lackner et al.
5878 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
Kolmogorov-Smirnov tests), Kruskal-Wallis H tests were applied to test
for differences betweenAFLP clusters to test for differences inMIC values.
For categorical data, chi-square tests were used. P values were calculated
with a two-sided significance level of   0.05. Statistical analyses for
susceptibility data were performed using SPSS v. 20 software (SPSS, Inc.,
Chicago, IL, USA). AFLP-based clusters 1, 3, 4, 5, 6a, 6b, 9a, 9b, and “no
cluster” were distinguished. P values below 0.05 were regarded as statisti-
cally significant.
RESULTS
An UPGMA tree generated with AFLP electropherograms (see
Fig. S1 in the supplemental material) yielded 10 main groups
(AFLP1 to -10) at a cutoff at 28% similarity, three of which were
subdivided into approximate subclusters (AFLP2a to -c, AFLP6a
and -b, and AFLP9a and -b) (see Table S1 in the supplemental
material). Lomentospora prolificans (n  39), a phylogenetically
remote species, was included for comparison. Seven of the main
groups contained at least one type strain of a described species.
AFLP group 1 contained the type strain ofP. ellipsoidea, group 2 of
S. dehoogii, group 3 of P. angusta, group 6 of S. boydii, group 7 of
S. minutisporum, group 9 of S. apiospermum, and group 10 of S.
aurantiacum. Groups 4 and 5were unnamed. The AFLP groups 9a
and 9b were randomly distributed in trees of BT2 and ITS within
S. apiospermum, while AFLP groups 2a and 2b did not match with
any BT2 group within S. dehoogii/S. deficiens (see Table S1). Some
heterogeneity with two groups (AFLP5 and 6) was noted in S.
boydii below the cutoff; group 5 was recognizable as an unsup-
ported subgroup in BT2 (see Fig. S2).
The BT2 data set had a total number of sites (excluding gaps/
missing data) of 232 bp and a total number of mutations of 66; 56
sites were polymorphic (7 singletons and 49 parsimony informa-
tive), and 176 sites were monomorphic. Parsimony-informative
sites consisted of 41 sites with 2 variants, 7 sites with 3 variants,
and 1 site with 4 variants.We also determined nucleotide diversity
per site (	  0.04008), average number of nucleotide differences
(k 9.30), number of haplotypes (h 36), and haplotype diver-
sity (Hd 0.952).
Phylogenetic sorting of BT2 sequences of 121 strains using
Ward’s averaging demonstrated the presence of ninemain clusters
approximately matching with AFLP groups 1 to 9. A maximum
likelihood tree of the same data (constructed with the TN93I
model and 1,000 bootstrap replications, and S. desertorum CBS
489.72 as the out-group) exhibited the same topology and clade
distinction (see Table S1 in the supplemental material), but de-
grees of statistical support of the nodes were variable (see Fig. S2).
The groups contained the type strains of all Scedosporium species
and are currently referred to as S. aurantiacum (AFLP10; BT2
bootstrap support 99%), S. minutisporum (AFLP7; 100%), S. ap-
iospermum (AFLP9; 47%), S. dehoogii including S. deficiens
(AFLP2; 89%), P. angusta (AFLP3; no bootstrap support), S. boy-
dii (AFLP5 and -6; 84%), P. ellipsoidea (AFLP1; no bootstrap sup-
port), and an unnamed group (AFLP4; no bootstrap support). In
contrast, several branches were supported that did notmatchwith
known species delimitations. AFLP3 matched with an unnamed
clade with 83% support, two supported clades were found para-
phyletic to AFLP group 9, and AFLP group 2 showed significant
diversity (see Fig. S2).
Six of the groups listed above were separated from each other
in BT2 by two or more fixed mutations, whereas two (AFLP
groups 1 and 3)were characterized by a combination ofmutations
(see Table S2 in the supplemental material). Three groups differ-
ing by limited numbers of markers contained the type strains of P.
ellipsoidea (AFLP1), P. angusta (AFLP3), and S. boydii (AFLP6).
The number of fixed mutations was minor relative to the number
of variables, while in the unambiguous species S. minutisporum
and S. aurantiacum, the number of fixedmutations was equally as
large as or larger than the number of polymorphic sites (see Table
S2). Recombination events were calculated in the BT2 data ac-
cording to Hudson and Kaplan (39) implemented in DNASP v.
5.10. In 232 positions analyzed (excluding sites with gaps/missing
data), the number of pairs of sites with four gametic types was 88,
yielding a minimum number of recombination events (Rm) of 9.
In contrast, the pairwise homoplasy index (PHI) test (imple-
mented in SplitsTree v. 4.8) yielded no significant evidence of
recombination (P 0.495). The average number of pairwise dif-
ferences between andwithin populations (Fst)was calculated con-
sidering the AFLP groups as separate populations (Table 1).
GroupAFLP8was not distinct fromAFLP1 and 6. At a cutoff value
of 0.25, no gene flowwas detected between any of the populations.
In a neighbor network constructed with SplitsTree v. 4.8, AFLP
groups 4 and 9 were not separated (Fig. 1). Group AFLP3 re-
mained separate from the combined groups 1, 6, and 9. The ge-
netic isolation of populations is confirmed by the Fst values (Table
1), which in most cases are higher than 0.25, while AFLP1, 6, and
8 did not show evidence of population isolation. The same soft-
ware was used to calculate evidence of recombination events.
With ITS using different algorithms, only seven (A to G, in-
TABLE 1 Fst values considering AFLP groups as separate populationsa
AFLP (no. of
sequences;
no of
haplotypes)
Fst value for AFLP (no. of sequences; no of haplotypes):
AFLP2 (19; 7) AFLP1 (15; 2) AFLP3 (15; 5) AFLP4 (3; 2) AFLP5 (5; 1) AFLP6 (20; 4) AFLP7 (4; 2) AFLP8 (2; 2) AFLP9 (24; 6)
AFLP1 (15; 2) 0.86529
AFLP3 (15; 5) 0.80798 0.69255
AFLP4 (3; 2) 0.85538 0.8806 0.66369
AFLP5 (5; 1) 0.89129 0.90909 0.84736 0.94737
AFLP6 (20; 4) 0.84515 0.74178 0.7555 0.86914 0.87474
AFLP7 (4; 2) 0.89874 0.96346 0.91069 0.94815 0.98246 0.94254
AFLP8 (2; 2) 0.76902 0.0 0.42052 0.63158 0.33333 0.02729 0.84211
AFLP9 (24; 6) 0.83505 0.82062 0.6045 0.67277 0.89714 0.82849 0.92038 0.60203
AFLP10 (5; 2) 0.89906 0.97573 0.94587 0.96791 0.98529 0.96007 0.97572 0.89252 0.94449
a Average numbers of pairwise differences between and within populations established with DNASP v. 5.10. Threshold value is 0.25.
Scedosporium Susceptibility and Diversity
October 2014 Volume 58 Number 10 aac.asm.org 5879
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
cluding the out-group) of the nine main groups were recognized
due to lower variability of this gene (see Table S1 in the supple-
mental material). Groups AFLP1, -3, -4, -5, and -6 were not dis-
tinguished, and group 3 deteriorated in two unsupported
branches. The species S. aurantiacum, S. desertorum, and S.minut-
isporum were unambiguously separated at high-bootstrap values
(data not shown). Group AFLP2, containing representative
strains of S. deficiens and S. dehoogii, varied 2.7% in BT2 and 0.9%
in ITS. ITS differences were based almost exclusively on variations
of four fixed mutations. BT2 also yielded two main subgroups,
differing by five fixedmutations. Three approximate AFLP groups
(2a to -c)were recognizable, with tested strains of group 2amatch-
ing with S. deficiens. However, significant conflicts between topol-
ogies of the different partitions were observed among ITS, BT2,
and AFLP (see Table S1), and therefore we found the two species
inseparable.
The position of group AFLP3 was verified with a centroid ap-
proach based on ITS versus BT2. For BT2, the optimal predicted
similarity value was 97.6%, while for ITS this value was 99.26%.
Groups were clearly separated from each other, except P. angusta
(AFLP3), which was not separated from S. apiospermum or from
S. boydii with BT2 or ITS data, respectively. However, when P.
angusta (AFLP3) was postulated as a part of S. boydii (AFLP1/6),
BT2 sequences of P. angustamerged into the group of S. apiosper-
mum (Fig. 2) at a similarity value of 99.03%, while with ITS, P.
angustamerged with S. boydii at a similarity value of 99.26%. This
suggests that AFLP3 takes an intermediate position between S.
boydii and S. apiospermum. In Fig. 3, sequences associatedwith the
same taxon share the same color, i.e., have similarity values greater
than or equal to the optimal predicted similarity.
A minimum spanning tree of AFLP data (see Fig. S3 in the in
the supplemental material) limited to the S. apiospermum/S. boy-
dii group (AFLP groups 1, 3, 4, 5, 6, and 9) showed these species as
a complex of large, variable clouds, with S. apiospermum (AFLP9)
in particular as awidely variable species. In the S. boydii area, some
groups were individualized, including AFLP groups 5 and 6 of S.
boydii, AFLP3 with the type strain of P. angusta, AFLP1 with the
type strain of P. ellipsoidea, and unnamed group AFLP5. The
number of AFLP clusters in relation to the total sample size was
large. When plotting geographic origin on the tree, no significant
structuring was observed, except for some sampling bias because
of overrepresentation of European strains (data not shown). A
possible relationship with strain origin (clinical versus environ-
mental) was not possible because of a strong sampling bias, with
mainly clinical isolates having been collected systematically.
Kruskal-Wallis H tests comparing antifungal susceptibilities of
clinical versus environmental strains over all AFLP groups yielded
no statistically significant differences inMICs for amphotericin B,
FIG 1 Neighbor network of Scedosporium based on BT2 data constructed with SplitsTree v. 4.8 and compared with AFLP grouping. Note that in S. apiosper-
mum/S. boydii, two branches are present with a heterogeneous Pseudallescheria angusta group in an intermediate position.
Lackner et al.
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anidulafungin, micafungin, posaconazole, or voriconazole. This
result was supported by chi-square tests using categorization (sus-
ceptible/intermediate/resistant [S/I/R]) instead of numerical
MICs (see Tables S3a to c in the supplemental material). MIC
values of Lackner et al. (10) comparing AFLP groups using
Kruskal-Wallis H tests were found to differ in susceptibility
against amphotericin B, anidulafungin, and micafungin (see Ta-
ble S3). Specifically, pairwise comparisons with correction for
multiple testing (Bonferroni) revealed significant differences for
anidulafungin between clusters 9a/6b and formicafungin between
clusters 1/6b, 1/3, 9a/6b, and 9a/3. For amphotericin B, no pair-
wise comparison was significant after Bonferroni correction. No
statistically significant differenceswere observed for amphotericin
B, voriconazole, and posaconazole.
Individual strains within some of the AFLP groups differed
remarkably in susceptibility to antifungal compounds, ranging
from low to high MICs. Figure 4 shows median values with first-
and third-quartile log2 MICs, with outliers and extreme outliers
indicated. Distributions are visualized by plotting antifungal data
(S/I/R) on minimum spanning trees of AFLP groups, exemplified
by amphotericin B (Fig. 3A). In amphotericin B, 111 strains were
found to have low MICs and 43 to have high MICs, while only 10
had medium MICs, underlining the pronounced differences in
MICs between isolates. The distribution of strains with highMICs
over the S. apiospermum/S. boydii complex ismore or less random
(Fig. 3A), as was also found with other drugs tested (data not
shown). Multiresistance was analyzed by plotting correlations for
azoles (respectively for echinocandins) on the AFLP minimum
spanning tree of the S. apiospermum/S. boydii complex (Fig. 3A to
C). In the comparison of the azoles voriconazole/posaconazole,
most strains had low MICs for both compounds (L/L; n  205),
while 51 had highMICs for posaconazole, but highMICs for vori-
conazole were exceptional. With echinocandins, most strains had
low MICs for anidulafungin/micafungin (L/L; n  160); of the
strains with high MICs for anidulafungin, many strains had low
MICs for micafungin (H/L; n  34), and only a few isolates had
highMIC values for both substances (H/H; n 39), indicating an
absence of correlation of resistance.
DISCUSSION
Emerging resistance against antifungal agents is likely to dissemi-
nate differentially depending on the mode of exchange of genetic
material between lineages, and therefore knowledge of patterns of
diversity and mating is essential for understanding the spread of
resistance over populations. Gilgado et al. (24) investigated mat-
ing systems in the genus Scedosporium and suggested that there
were fundamental differences between species. In particular, S.
boydii and S. apiospermum were judged to be homo- and het-
erothallic, respectively. Borderlines between species were judged
to be clearly defined in a relatively limited data set.
The present study confirms earlier investigations in that Sce-
dosporium (including its obsolete teleomorph name Pseudall-
FIG 2 Distribution of BT2 sequences representing multidimensional distances from centroid. Pseudallescheria angusta takes an intermediate position between
S. apiospermum and S. boydii.
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escheria [38]) comprises a number of different species, separated
from each other by strictly concordant multilocus parsimony-in-
formative sequences and AFLP data. Variability is noted in both
genes studied (BT2 as well as in ITS) and is also recognized in
AFLP profiles, although degrees of variability differ between
groups. Unambiguous separation was achieved between S. deser-
torum, S. minutisporum, and S. aurantiacum, while S. prolificans is
also known to constitute a separate entity, recently even at the
generic level L. prolificans (11, 25). The remaining species formed
two complexes, one consisting of S. deficiens/S. dehoogii and an-
other comprising S. apiospermum, P. angusta, P. ellipsoidea, and S.
boydii. ITS is known to have a lower degree of discriminatory
power thanBT2. Twomajor groups were recognized in S. dehoogii
when markers were studied individually, suggesting the existence
of a second species, S. deficiens (14). However, despite the signifi-
cant distances in both genes, multilocus analysis (ITS, BT2, and
AFLP) showed that the groups were not concordant and recom-
bination between the groups was frequent (6 recombinants in a
total set of 20 strains) (see Table S1 in the supplemental material).
The latter suggests that the more recently described S. deficiens
(15) belongs to the same biological species as S. dehoogii.
Differences within the complex S. apiospermum/S. boydii were
even smaller. The groups were difficult to delineate with BT2 data
when distance-based algorithms were used, partly due to the fact
that the number of singleton mutations led to an overabundance
of SNP-based haplotypes. Fixed mutations were observed only
when the complex was further subdivided into four entities, pro-
visionally indicated as S. apiospermum (AFLP9), P. angusta
(AFLP3), P. ellipsoidea (AFLP1), and S. boydii (AFLP5 and -6).
With BT2 data with the Tamura-Nei TN93GImodel, where G is
the gamma distributed rate variation among sites and I is the pro-
portion of invariable sites (extent of static, unchanging sites) in a
dataset, S. boydii deteriorated into three groups, two of which
lacked statistical support (see Fig. S2), and included P. ellipsoidea
(AFLP1) and P. angusta (AFLP3). In the neighbor network in
SplitsTree v. 4.8 (Fig. 1) AFLP3 was an amalgamate of deviating
strainswhich in a centroid approachwere intermediate between S.
boydii and S. apiospermum. Fst values suggest complete separation
of lineages (Table 1). The complex thus consists of a series of very
close lineages showing limited gene flow. AlthoughDNASP v. 5.10
showed 9 recombination events, the PHI test showed no statisti-
cally significant evidence for recombination (P  0.495) and
hence the existence of intrinsic mating barriers is hypothesized.
Possibly AFLP4 and AFLP8 are recombinant, suggesting mating
between S. apiospermum and S. boydii at low frequency. Gilgado et
al. (24) noted that two strains of S. apiospermum crossedwith both
plus and minus mating types. The sexuality of Scedosporium thus
remains enigmatic.
While in heterothallic fungi recombination serves to exchange
traits to bring about change, in homothallic fungi sexual repro-
duction aims to conserve recently manifested mutations for the
next generation. Our study showed that recombination is rare
between closely related entities in Scedosporium. Populations seem
to expand sympatrically, suggesting high degrees of homothal-
lism. There is nomatch of lineages in the S. apiospermum/S. boydii
group with clinical data or geography (data not shown).
Scedosporium aurantiacum is known to differ from the remain-
ing taxa in particular for patterns of susceptibility to posaconazole
(10). Lomentospora prolificans is deviant in all respects, being one
of the most recalcitrant fungi known (26). Differences between
FIG 3 Antifungal susceptibilities per strain plotted on minimum spanning
tree generated fromAFLP data. (A) Amphotericin B (AMB). Green, lowMICs
(L); yellow, medium MICs (M); red, high MICs (H). (B) Cross-resistance to
echinocandins anidulafungin andmicafungin. Bright blue,M/H (n 2); blue,
M/L (n  22); yellow, insufficient growth/insufficient growth (n  10);
salmon pink, insufficient growth (failed to form sufficient amount of myce-
lium in growth control within 72 h in three biological replicas)/L (n 6); red,
H/H (n  39); bright pink, H/M (n  2); bright green, L/H (n  1); purple,
H/L (n 34); green, L/L (n 160). (C)Cross-resistance to azoles voriconazole
and posaconazole. Yellow, insufficient growth/insufficient growth (n  10);
red, H/H (n 1); brown,H/L (n 1); purple,M/H (n 6); bright green, L/M
(n 3); bright blue, L/H (n 51); dark green, L/L (n 205).
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susceptibility patterns of S. apiospermum and S. boydii are very
small (10); only differences between AFLP subgroups were re-
vealed, possibly biased by sampling effects and insufficient sample
sizes. We analyzed the differences in more detail by plotting pro-
files of resistance against antifungals on minimum spanning trees
generated from AFLP data, exemplified by amphotericin B (Fig.
3A). Amphotericin B has been found to have limited efficacy
against activity in cerebral scedosporiosis in animal experiments
(27).Withmost of the compounds tested, strainswere classified as
either susceptible or resistant, with only a few isolates in between
these extremes, and distributions over AFLP groups were largely
random. Figure 3B and C demonstrate that there is little correla-
tion between susceptibility profiles (multiresistance being rare),
suggesting that azole versus echinocandin resistance is governed
by different mutations.
Significant clinical differences between Scedosporium species
and relatives are known to exist, in that, e.g.,L. prolificans ismainly
involved in disseminated infections in immunocompromised
hosts and is not observed in the near-drowning syndrome (8).
However, differences within the S. apiospermum/S. boydii com-
plex are small. Kaltseis et al. (28) noted that S. boydii is more
frequently found in clinical specimens than S. apiospermum. This
difference was not observed by Lackner et al. (29). Bernhardt et al.
(30) noted that S. boydii had an incidence equal to or lower than
that of S. apiospermum in pulmonary colonization of patients with
cystic fibrosis. In an attempt to quantify clinical significance of
species, we distinguished four main types, environmental, trau-
matic (sub)cutaneous, respiratory colonization and infection, and
systemic anddisseminated infection.No significant differencewas
revealed within the S. apiospermum/S. boydii complex. This result,
together with limited antifungalMIC differences between the spe-
cies, has led to the conclusion that as yet no medically relevant
FIG 4 Box plots of log2-transformed MIC values for the AFLP-based clusters. (A) Amphotericin B (AMB), (B) anidulafungin (ANI), (C) micafungin (MICA),
(D) posaconazole (POS), and (E) voriconazole (VOR). Central lines in each box denote the median, and the lower/upper rims represent first/third quartiles
(Q1/Q3); the whiskers extend to 1.5 times the height of the box (or to theminimum/maximumvalue). Outliers are shown by circles if values are up to three times
the height of the boxes or by asterisks if values are more than three times the height of the boxes (extreme outliers).
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difference between these two species is apparent. In the daily hos-
pital routine, identification with 96.3% confidence using the stan-
dard bar-coding gene ITS is sufficient for patient management.
Voriconazole is recommended as the first-line treatment (32); its
activity against S. apiospermum in vitro, in vivo, and in patients was
demonstrated in multiple studies (31–33). Resistance against this
compound was very rare. Posaconazole was found effective
against S. apiospermum complex members in vitro. According to
in vivo studies (murinemodels) and patient case reports, this drug
is effective (34–37), but in vitro susceptibility testing is mandatory
due to the occurrence of resistance. Anidulafungin and micafun-
gin may represent future therapeutic options, which, however,
remain to be evaluated by in vivo experiments.
The main clinically relevant species S. apiospermum/S. boydii
differ in anonymous markers, but antifungal resistance has a ran-
dom distribution within the species complex. Distinction of indi-
vidual species is useful for epidemiological questions but does not
contribute significantly to patient care.Whether or not the species
should be distinguished in daily routine practice is dependent on
the diagnostic question. Species distinction does not predict anti-
fungal resistance, and therefore testing of each strain prior to ther-
apy remains compulsory.
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